Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Olema Pharmaceuticals, Inc.OLMA · Entity 613 | CH. DISCOV. & NON-CLIN DEV OFF | February 02, 2026 | February 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Olema Pharmaceuticals, Inc.
Report date February 02, 2026 · Filed February 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.65 · Expires 2036-02-01 | Direct | 250,000 |
Reported balance
After 2026-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-02 · Grant · Acquired 250,000 · Balance 250,000 F1: 25% of the shares subject to the option vest on February 2, 2027, and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. |
| Performance Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.65 · Expires 2036-02-01 | Direct | 106,250 |
Reported balance
After 2026-02-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-02 · Grant · Acquired 106,250 · Balance 106,250 F2: The performance-based stock options will be eligible to vest during two distinct performance periods, each beginning on February 2, 2026 and ending on December 31, 2029 and December 31, 2030, respectively, based on the Issuer's stock price trading at certain pre-determined price thresholds as measured by the average closing price per share of the Issuer's stock over a consecutive thirty (30) day trading period during each such performance period. Once a price threshold is achieved, the portion of the award related to such threshold will vest upon the date set forth in the certification by the Compensation Committee certifying that such price threshold was achieved, subject to the Reporting Person's continuous service as of the applicable certification date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the option vest on February 2, 2027, and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
F2: The performance-based stock options will be eligible to vest during two distinct performance periods, each beginning on February 2, 2026 and ending on December 31, 2029 and December 31, 2030, respectively, based on the Issuer's stock price trading at certain pre-determined price thresholds as measured by the average closing price per share of the Issuer's stock over a consecutive thirty (30) day trading period during each such performance period. Once a price threshold is achieved, the portion of the award related to such threshold will vest upon the date set forth in the certification by the Compensation Committee certifying that such price threshold was achieved, subject to the Reporting Person's continuous service as of the applicable certification date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 02, 2026 Filed Feb 5, 2026 02:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantPerformance Stock Options (Right to Buy) · Derivative | 106,250 | $0.00 Strike: $25.65 | $0.00 |
DisclosureSEC source: 0001831216-26-000005 · form4-02042026_090205.xml · derivative · entry 2 Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,250 Underlying: Common Stock · 106,250 shares Expires 2036-02-01 F2 · derivative.exercise_date: The performance-based stock options will be eligible to vest during two distinct performance periods, each beginning on February 2, 2026 and ending on December 31, 2029 and December 31, 2030, respectively, based on the Issuer's stock price trading at certain pre-determined price thresholds as measured by the average closing price per share of the Issuer's stock over a consecutive thirty (30) day trading period during each such performance period. Once a price threshold is achieved, the portion of the award related to such threshold will vest upon the date set forth in the certification by the Compensation Committee certifying that such price threshold was achieved, subject to the Reporting Person's continuous service as of the applicable certification date. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 02:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $25.65 | $0.00 |
DisclosureSEC source: 0001831216-26-000005 · form4-02042026_090205.xml · derivative · entry 1 Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2036-02-01 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 2, 2027, and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| January 14, 2026 Filed Jan 15, 2026 02:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $4.87 | $0.00 |
DisclosureSEC source: 0001831216-26-000003 · form4-01142026_090101.xml · derivative · entry 10 Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| January 14, 2026 Filed Jan 15, 2026 02:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 35,003 | $28.99 | $1,014,736.97 |
DisclosureSEC source: 0001831216-26-000003 · form4-01142026_090101.xml · nonDerivative · entry 7 Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 542,761 F6 · price: The weighted average sale price for the transaction reported was $28.99, and the range of prices was between $28.80 and $29.39. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| January 14, 2026 Filed Jan 15, 2026 02:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 14,997 | $28.60 | $428,914.20 |
DisclosureSEC source: 0001831216-26-000003 · form4-01142026_090101.xml · nonDerivative · entry 6 Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 577,764 F5 · price: The weighted average sale price for the transaction reported was $28.60, and the range of prices was between $27.80 and $28.79. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| January 14, 2026 Filed Jan 15, 2026 02:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionCommon Stock | 50,000 | $4.87 | $243,500.00 |
DisclosureSEC source: 0001831216-26-000003 · form4-01142026_090101.xml · nonDerivative · entry 5 Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 592,761 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 02:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $4.87 | $0.00 |
DisclosureSEC source: 0001831216-26-000003 · form4-01142026_090101.xml · derivative · entry 9 Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 50,000 shares Expires 2033-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 02:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 200 | $28.49 | $5,698.00 |
DisclosureSEC source: 0001831216-26-000003 · form4-01142026_090101.xml · nonDerivative · entry 4 Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 542,761 Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 02:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 49,800 | $27.60 | $1,374,480.00 |
DisclosureSEC source: 0001831216-26-000003 · form4-01142026_090101.xml · nonDerivative · entry 3 Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 542,961 F4 · price: The weighted average purchase price for the transaction reported was $27.60, and the range of prices were between $27.35 and $28.21. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 02:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionCommon Stock | 50,000 | $4.87 | $243,500.00 |
DisclosureSEC source: 0001831216-26-000003 · form4-01142026_090101.xml · nonDerivative · entry 2 Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 592,761 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · balance_after: On December 23, 2025, the Reporting Person filed a Form 4 that contained a scrivener's error that resulted in the number of shares beneficially owned directly by the Reporting Person to be overstated by 120 shares. That error has been corrected in this Form 4. Read SEC document |
| January 12, 2026 Filed Jan 15, 2026 02:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 10,000 | $28.34 | $283,400.00 |
DisclosureSEC source: 0001831216-26-000003 · form4-01142026_090101.xml · nonDerivative · entry 1 Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 144,846 F1 · price: The weighted average sale price for the transaction reported was $28.34, and the range of prices were between $28.07 and $28.66. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. F2 · ownership.nature: The shares are held by Myles Properties Inc., of which the Reporting Person is President. Read SEC document |
| December 19, 2025 Filed Dec 24, 2025 02:41 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GiftCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001831216-25-000004 · form4-12242025_021245.xml · nonDerivative · entry 4 Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 542,881 Read SEC document |
| December 19, 2025 Filed Dec 24, 2025 02:41 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 6,046 | $31.39 | $189,783.94 |
DisclosureSEC source: 0001831216-25-000004 · form4-12242025_021245.xml · nonDerivative · entry 3 Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 551,881 F5 · price: The weighted average sale price for the transaction reported was $31.39, and the range of prices was between $31.00 and $31.595. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 19, 2025 Filed Dec 24, 2025 02:41 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 43,729 | $30.40 | $1,329,361.60 |
DisclosureSEC source: 0001831216-25-000004 · form4-12242025_021245.xml · nonDerivative · entry 2 Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 557,927 F4 · price: The weighted average sale price for the transaction reported was $30.40, and the range of prices was between $30.00 and $30.995. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided Read SEC document |
| December 19, 2025 Filed Dec 24, 2025 02:41 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 1,225 | $28.08 | $34,398.00 |
DisclosureSEC source: 0001831216-25-000004 · form4-12242025_021245.xml · nonDerivative · entry 1 Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 601,656 F1 · price: The weighted average sale price for the transaction reported was $28.08, and the range of prices was between $28.075 and $28.130. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. F2 · balance_after: On December 11, 2024, the Reporting Person filed a Form 4 that contained a scrivener's error that resulted in the number of shares beneficially owned directly by the Reporting Person to be understated by 60 shares. That error has been corrected in this Form 4. F3 · balance_after: Includes 4,488 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2025. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:20 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 205,000 | $0.00 Strike: $4.37 | $0.00 |
DisclosureSEC source: 0001415889-25-006160 · form4-03032025_090348.xml · derivative · entry 1 Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,000 Underlying: Common Stock · 205,000 shares Expires 2035-02-27 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 28, 2026 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| December 11, 2024 Filed Dec 12, 2024 00:56 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 300 | $9.39 | $2,817.00 |
DisclosureSEC source: 0001415889-24-029027 · form4-12122024_121200.xml · nonDerivative · entry 4 Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 598,333 F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F6 · price: The weighted average sale price for the transaction reported was $9.39, and the range of prices was between $9.31 and $9.74. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 11, 2024 Filed Dec 12, 2024 00:56 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 13,314 | $8.66 | $115,299.24 |
DisclosureSEC source: 0001415889-24-029027 · form4-12122024_121200.xml · nonDerivative · entry 3 Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 598,633 F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F5 · price: The weighted average sale price for the transaction reported was $8.66, and the range of prices was between $8.22 and $9.21. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 10, 2024 Filed Dec 12, 2024 00:56 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 12,452 | $9.38 | $116,799.76 |
DisclosureSEC source: 0001415889-24-029027 · form4-12122024_121200.xml · nonDerivative · entry 2 Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 611,947 F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F4 · price: The weighted average sale price for the transaction reported was $9.38, and the range of prices was between $8.89 and $9.67. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 09, 2024 Filed Dec 12, 2024 00:56 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantCommon Stock | 48,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029027 · form4-12122024_121200.xml · nonDerivative · entry 1 Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 624,399 F1 · shares: On November 11, 2022, the Reporting Person was granted certain performance restricted stock units ("PRSUs") for 75,000 shares, which were subject to vesting upon certification by the Compensation Committee of the Company's achievement of two different performance milestones. 35% of the award previously vested on November 20, 2023. On December 9, 2024, the Compensation Committee certified that the remaining 65% of the award vested based on achievement of certain performance criteria. F2 · balance_after: Includes 1,490 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2024. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 22:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 195,000 | $0.00 Strike: $15.25 | $0.00 |
DisclosureSEC source: 0001415889-24-002610 · form4-02052024_050218.xml · derivative · entry 1 Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 195,000 shares Expires 2034-01-31 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2025 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| November 22, 2023 Filed Nov 23, 2023 00:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 6,653 | $13.89 | $92,410.17 |
DisclosureSEC source: 0001415889-23-015458 · form4-11222023_071109.xml · nonDerivative · entry 4 Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 574,099 F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F6 · price: The weighted average sale price for the transaction reported was $13.89, and the range of prices was between $13.62 and $14.15. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| November 21, 2023 Filed Nov 23, 2023 00:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 200 | $15.32 | $3,064.00 |
DisclosureSEC source: 0001415889-23-015458 · form4-11222023_071109.xml · nonDerivative · entry 3 Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 580,752 F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F5 · price: The weighted average sale price for the transaction reported was $15.32, and the range of prices was between $15.28 and $15.35. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| November 21, 2023 Filed Nov 23, 2023 00:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 6,776 | $14.87 | $100,759.12 |
DisclosureSEC source: 0001415889-23-015458 · form4-11222023_071109.xml · nonDerivative · entry 2 Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 580,952 F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F4 · price: The weighted average sale price for the transaction reported was $14.87, and the range of prices was between $14.26 and $15.25. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| November 20, 2023 Filed Nov 23, 2023 00:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantCommon Stock | 26,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-015458 · form4-11222023_071109.xml · nonDerivative · entry 1 Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 587,728 F1 · shares: On November 11, 2022, the Reporting Person was granted certain performance restricted stock units ("PRSUs") for 75,000 shares, which are subject to vesting upon certification by the Compensation Committee of the Company's achieving two different performance milestones. The Compensation Committee certified on November 20, 2023 that 35% of the award vested based upon the certification by the Compensation Committee as to certain performance criteria. F2 · balance_after: Includes 208 shares acquired under the issuer's Employee Stock Purchase Plan on November 15, 2023. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 22:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 200 | $17.61 | $3,522.00 |
DisclosureSEC source: 0001415889-23-015041 · form4-11132023_051101.xml · nonDerivative · entry 1 Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 561,270 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated June 20, 2023. F2 · price: The weighted average sale price for the transaction reported was $17.61, and the range of prices were between $17.52 and $17.69. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| November 03, 2023 Filed Nov 4, 2023 01:39 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 541 | $17.51 | $9,472.91 |
DisclosureSEC source: 0001415889-23-014792 · form4-11042023_011159.xml · nonDerivative · entry 3 Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 561,470 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated June 20, 2023. F4 · price: The weighted average sale price for the transaction reported was $17.51, and the range of prices were between $17.50 and $17.53. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| November 02, 2023 Filed Nov 4, 2023 01:39 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 3,332 | $15.36 | $51,179.52 |
DisclosureSEC source: 0001415889-23-014792 · form4-11042023_011159.xml · nonDerivative · entry 2 Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 562,011 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated June 20, 2023. F3 · price: The weighted average sale price for the transaction reported was $15.36, and the range of prices were between $15.01 and $15.74. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| November 01, 2023 Filed Nov 4, 2023 01:39 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 6,668 | $15.02 | $100,153.36 |
DisclosureSEC source: 0001415889-23-014792 · form4-11042023_011159.xml · nonDerivative · entry 1 Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 565,343 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated June 20, 2023. F2 · price: The weighted average sale price for the transaction reported was $15.02, and the range of prices were between $15.00 and $15.09. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 19, 2023 Filed Sep 21, 2023 21:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 20,000 | $12.67 | $253,400.00 |
DisclosureSEC source: 0001415889-23-013474 · form4-09212023_050902.xml · nonDerivative · entry 1 Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 572,011 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated June 20, 2023. F2 · price: The weighted average sale price for the transaction reported was $12.67, and the range of prices were between $12.31 and $12.85. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · balance_after: Includes 1,446 shares acquired under the issuer's Employee Stock Purchase Plan on May 15, 2022, and 7,664 shares acquired under the issuer's Employee Stock Purchase Plan on May 15, 2023. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 22:32 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $4.87 | $0.00 |
DisclosureSEC source: 0001209191-23-006289 · doc4.xml · derivative · entry 1 Myles David C. · CIK 0001831216 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-01-31 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 00:15 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 118,750 | $0.00 Strike: $7.02 | $0.00 |
DisclosureSEC source: 0001415889-22-001061 · form4-02032022_040238.xml · derivative · entry 1 Myles David C. · CIK 0001831216 · CHIEF DEVELOPMENT OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,750 Underlying: Common Stock · 118,750 shares Expires 2032-01-31 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 21:03 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 10,000 | $10.30 | $103,000.00 |
DisclosureSEC source: 0001415889-21-005860 · form4-12142021_011237.xml · nonDerivative · entry 1 Myles David C. · CIK 0001831216 · CHIEF DEVELOPMENT OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 582,901 F1 · price: T he weighted average sale price for the transaction reported was $10.30, and the range of prices was between $10.23 and $10.50. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. F2 · balance_after: Includes 589 shares acquired under the issuer's Employee Stock Purchase Plan on May 14, 2021, and 491 shares acquired under the issuer's Employee Stock Purchase Plan on November 15, 2021. Read SEC document |
| November 23, 2020 Filed Nov 23, 2020 21:34 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | ConversionSeries A Convertible Preferred Stock · Derivative | 154,846 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-059976 · doc4.xml · derivative · entry 5 Myles David C. · CIK 0001831216 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 154,846 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock. F1 · price: The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock. F1 · derivative.exercise_date: The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock. F1 · derivative.expiration_date: The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock. F3 · ownership.nature: The shares are held by Myles Properties Inc., of which the Reporting Person is President. Read SEC document |
| November 23, 2020 Filed Nov 23, 2020 21:34 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | ConversionSeries A Convertible Preferred Stock · Derivative | 12,831 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-059976 · doc4.xml · derivative · entry 4 Myles David C. · CIK 0001831216 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 12,831 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock. F1 · price: The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock. F1 · derivative.exercise_date: The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock. F1 · derivative.expiration_date: The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock. F2 · ownership.nature: The shares are held by The Myles Family Revocable Inter Vivos Trust, of which the Reporting Person is trustee. Read SEC document |
| November 23, 2020 Filed Nov 23, 2020 21:34 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | ConversionCommon Stock | 154,846 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-059976 · doc4.xml · nonDerivative · entry 2 Myles David C. · CIK 0001831216 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 154,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock. F3 · ownership.nature: The shares are held by Myles Properties Inc., of which the Reporting Person is President. Read SEC document |
| November 23, 2020 Filed Nov 23, 2020 21:34 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | ConversionCommon Stock | 12,831 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-059976 · doc4.xml · nonDerivative · entry 1 Myles David C. · CIK 0001831216 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 12,831 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock. F2 · ownership.nature: The shares are held by The Myles Family Revocable Inter Vivos Trust, of which the Reporting Person is trustee. Read SEC document |
| November 18, 2020 Filed Nov 19, 2020 23:59 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 179,340 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001209191-20-059524 · doc4.xml · derivative · entry 2 Myles David C. · CIK 0001831216 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,340 Underlying: Common Stock · 179,340 shares Expires 2030-11-17 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on November 18, 2021 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| June 15, 2020 Filed Nov 19, 2020 23:59 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantCommon Stock | 143,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-059524 · doc4.xml · nonDerivative · entry 1 Myles David C. · CIK 0001831216 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 591,821 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.